Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REALM-DCM: ARRY-371797 (PF-07265803) in LMNA-related Dilated Cardiomyopathy
jRCT2051210191Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in dilated cardiomyopathy (DCM) comparing PF-07265803 400 mg BID with Placebo BID (2 arms). Primary endpoint: Change from baseline in 6-minute walk test (6MWT) at Week 24. Started Jul 2022; status: completed.
02
Drugs
emprumapimod
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on jRCT2051210191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210191.